Positioning itself to secure revenues in a post-Pandemic environment desperate to mitigate potential risk of re-transmission of COVID-19 or similar future viruses, Integumen has today announced that its subsidiary, Labskin, will immediately begin the testing of anti-viral treatments on Labskin cloned human skin coated with SARS-CoV-2 virus.
In the first instant, this will be to investigate the use of consumer and dental care products that have the potential to influence the spread of the disease.
Such a detailed understanding could significantly influence or provide regulatory guidelines for their future design, composition and/or utilisation.
In this respect, Integumen appears to be pre-empting international governmental demands to be better equipped and informed in order to fight the spread of any future virus infections across their wider communities.
Identifying products to mitigate the infection risk
Labskin has secured access to the SARS-CoV-2 virus Category 3 laboratory at the University of Aberdeen to assess the strain ‘SARS-CoV-2 England/2/2020’ regarding its transmissibility impact to and from human skin without exposing human volunteers to potentially hazardous clinical trial contamination risk. As such, strictly controlled in vitro tests will undertake the following examinations:
• Study the transferability of viral particles from materials to skin
• Assess the ability of the virus to remain infective while on the skin surface
• Quantify the efficacy of mouthwash and dental care products
• Quantify the efficacy of soap washing and hand sanitisers
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Integumen plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned